Aug 14, 2017· Anticoagulants, commonly known as blood thinners, prevent or treat blood clot formation. These drugs can be administered to prevent strokes and heart attacks caused by blood clots, or they can be used to treat deep vein thrombosis or pulmonary embolism (blood clot in the lungs).
Oral anticoagulants or 'blood thinners' were proposed in 400 BC during the time of Hippocrates. The first paper entitled 'Coumadin (warfarin) sodium – a new anticoagulant' was published in 1956 .
Besides warfarin, you and your doctor will take a look at these new drugs: Apixaban (Eliquis) Dabigatran (Pradaxa) Edoxaban (Savaysa) Rivaroxaban (Xarelto)
Dec 02, 2015· In the last few years, FDA has approved three new oral anticoagulant drugs – Pradaxa (dabigatran), Xarelto (rivaroxaban), and Eliquis (apixaban).
Anticoagulants are drugs that treat blood clots, and help prevent blood clot formation in the veins and arteries. Common side effects of these drugs are bruises, diarrhea, fever, intestinal gas, and headache. These drugs are prescribed to patients to treat and prevent a variety of diseases and conditions (DVT, pulmonary embolism, blood clot during atrial fibrillation).
Aug 26, 2016· Anticoagulants are the drugs of choice to prevent or treat these conditions. For decades, warfarin and heparin were the mainstay of treatment, but the development of new anticoagulant drugs is constantly enlarging the pharmaceutical armamentarium.
View list of generic and brand names of drugs used for treatment of Anticoagulants (Blood Thinners ). You can find more information including dosage, side effects of the Anticoagulants (Blood .
Coumarins and indandiones. Warfarin is a coumarin, and the only coumarin available in the U.S for human use. It works by limiting the availability of vitamin K, a vitamin that is necessary for the blood coagulation pathway to produce clotting factors II, VII, IX, and X. This decreases the blood's ability to clot.
Jun 30, 2017· On June 23, 2017, a new anticoagulant drug called BevyxXa (betrixaban) was approved by the FDA for the prevention of venous thromboembolism and pulmonary embolism. This drug acts as a direct Factor Xa inhibitor, similar to the other anticoagulant drugs Eliquis, Savaysa, and Xarelto.
Approval of New Oral Anticoagulant Drugs The continued quest for an 'ideal anticoagulant' led to the US FDA's recent approval of dabigatran etexilate, a prodrug for dabigatran (Pradaxa .